Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 4Terminated 2Recruiting 2Unknown 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Lymphoma, Large B-Cell, Diffuse 57Lymphoma, Non-Hodgkin 20Lymphoma 17Lymphoma, Mantle-Cell 14Lymphoma, Follicular 12Recurrence 10Leukemia, Lymphocytic, Chronic, B-Cell 10Burkitt Lymphoma 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma, B-Cell, Marginal Zone 4Lymphoma, B-Cell 4Hodgkin Disease 4Myelodysplastic Syndromes 3Waldenstrom Macroglobulinemia 2Neoplasms 2Lymphoma, Large-Cell, Immunoblastic 2Leukemia 2Dendritic Cell Sarcoma, Interdigitating 2Pyloric Stenosis, Hypertrophic 1Plasmablastic Lymphoma 1Neuroblastoma 1Neoplasms by Histologic Type 1Myasthenia Gravis 1Melanoma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell 1Lymphoma, Large-Cell, Anaplastic 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Acute 1Leukemia, Myeloid, Accelerated Phase 1

Interventions

spartalizumab 2pegaspargase 2Methylprednisolone 2Etoposide 2Dexamethasone 2toripalimab 1ruxolitinib 1Valproic Acid 1Valganciclovir 1Rituximab 1Liquid Biopsy 1Lenalidomide 1Gemcitabine 1Doxorubicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Epstein-Barr Virus Infections × Rituximab × Clear all
NCT04507477 2022-08-02

Ex-vivo Delivery of Rituximab to Prevent PTLD in EBV Mismatch Lung Transplant Recipients: A Pilot Trial

University Health Network, Toronto

Phase 1/2 Unknown
10 enrolled

Epstein-Barr Virus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡